

*Hong Kong Stock Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



開拓藥業有限公司 \*  
**KINTOR PHARMACEUTICAL LIMITED**

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock code: 9939)**

**VOLUNTARY ANNOUNCEMENT**

**KX-826 Received The INCI Designation**

This is a voluntary announcement made by Kintor Pharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) to update its shareholders and potential investors on the latest information related to the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that its in-house developed KX-826 has recently received the International Nomenclature Cosmetic Ingredient (the “**INCI**”) review approval from the International Cosmetic Ingredient Nomenclature Committee. The assigned INCI name is Methylpyridinyl Fluoromethoxybenzotrile Dimethyloxothioimidazolidine. INCI names are systemic names recognized worldwide for the identification of cosmetic ingredients and are cited by product labeling regulations in many countries. The assignment would facilitate the global launch of the Company's functional cosmetics with KX-826 as the main ingredient.

**Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:** There is no assurance that KX-826 will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board  
**KINTOR PHARMACEUTICAL LIMITED**

**Dr. Youzhi Tong**  
*Chairman of the Board, Executive Director and  
Chief Executive Officer*

Hong Kong, 4 June 2024

*As at the date of this announcement, the executive Directors are Dr. Youzhi Tong, Dr. Qun Lu and Dr. Xiang Ni; the non-executive Directors are Mr. Weipeng Gao, Ms. Geqi Wei and Mr. Chengwei Liu; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.*

*\* For identification purpose only*